News Sentiment

BBOT sentiment intelligence

BridgeBio Oncology Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.56 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+2.9% over one week, +13.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded by Wall Street Zen to "Sell" Rating

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 2.9% Price confirming higher
Trend fit Trend inactive 13.2% over four weeks
Fair value -16.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 43
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 8
TradingView 8
MarketBeat 4
Seeking Alpha 3
Investing.com 3
simplywall.st 3
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 12
Analyst action 9
Deals and strategy 6
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
MarketBeat Direct company coverage

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded by Wall Street Zen to "Sell" Rating

Wall Street Zen has upgraded BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a "strong sell" to a "sell" rating, while the overall analyst consensus remains a "Moderate Buy" with an average target price of $24.80. The company reported a significant loss per share for its lates

Tone
Neutral 50/100
Event
Analyst action
Published
18 Jul 2026 06:14
Source
MarketBeat
Seeking Alpha Direct company coverage

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics (BBOT) maintains a Buy rating despite a recent stock decline, due to its promising KRAS/RAS-targeted drug candidates. Key data readouts for its lead asset, BB-8520, which has shown strong efficacy in KRAS G12C NSCLC, are expected in the second half

Tone
Positive 92/100
Event
Analyst action
Published
13 Jul 2026 11:20
Source
Seeking Alpha
Investing.com Direct company coverage

JPMorgan initiates BridgeBio Oncology stock with overweight rating

JPMorgan initiated coverage on BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) with an overweight rating and a price target of $27.00, citing the company's precision oncology approach. The stock, currently trading significantly below the target, has gained 6.3% recently. The ba

Tone
Positive 73/100
Event
Analyst action
Published
08 Jul 2026 12:40
Source
Investing.com
Investing.com South Africa Direct company coverage

JPMorgan initiates BridgeBio Oncology stock with overweight rating By Investing.com

JPMorgan initiated coverage on BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) with an overweight rating and a price target of $27.00, citing significant upside potential from its current trading price of $8.29. The investment bank highlighted the company's precision oncology a

Tone
Positive 77/100
Event
Analyst action
Published
08 Jul 2026 08:10
Source
Investing.com South Africa
Investing.com India Direct company coverage

Form 13D/A BridgeBio Oncology Therapeutics For: 6 July By Investing.com

This article reports that a Form 13D/A was filed for BridgeBio Oncology Therapeutics on July 6. The filing is a public disclosure related to significant ownership in a company. Further details of the filing are not included in this provided text.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 02:20
Source
Investing.com India
Stock Titan Direct company coverage

Cormorant funds restructure 22.3% BridgeBio Oncology (BBOT) stake, add lock-up

Cormorant-affiliated investors, led by Bihua Chen, have restructured their 22.32% beneficial ownership in BridgeBio Oncology Therapeutics (BBOT). This involved a pro rata distribution of 4,528,186 shares from Helix Holdings II LLC to other Cormorant funds (Fund III, Fund V, and M

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 00:11
Source
Stock Titan
Stock Titan Direct company coverage

BridgeBio Oncology (BBOT) CMO uses 1,047 shares to cover RSU tax bill

BridgeBio Oncology Therapeutics, Inc.'s Chief Medical & Development Officer, Ben Yong, had 1,047 shares of common stock withheld on July 1, 2026. This transaction covered tax obligations from vesting restricted stock units at a price of $7.80 per share, and was an automatic tax-w

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

BBOT (BBOT) COO Idan sees 343 shares withheld to cover RSU tax bill

BridgeBio Oncology Therapeutics, Inc. (BBOT) COO & Principal Financial Officer Elmelech Idan had 343 shares of common stock withheld to cover tax obligations related to vesting restricted stock units. This was a non-open-market transaction for tax purposes, not a trade. Following

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

BridgeBio Oncology (NASDAQ: BBOT) officer reports tax-withheld RSU share disposition

BridgeBio Oncology Therapeutics, Inc.'s Principal Accounting Officer, Marc Cobo, reported a disposition of 125 shares of Common Stock. This transaction was for tax withholding purposes in connection with the vesting of restricted stock units, not an open-market sale. Following th

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

Tax withholding trims BridgeBio Oncology (BBOT) CEO Beltran’s share count

BridgeBio Oncology Therapeutics, Inc. (BBOT) CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition, not an open-market sale, and Beltran no

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

BBOT SEC Filings - BridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms

This article provides a comprehensive overview of BridgeBio Oncology Therapeutics, Inc. (BBOT) SEC filings, including 10-K, 10-Q, and 8-K forms, catering to investors and traders. It details several recent filings such as a Q3 2025 loss and liquidity report, an 8-K announcing qua

Tone
Neutral 50/100
Event
Balance sheet
Published
03 Jul 2026 22:39
Source
Stock Titan
Market source Direct company coverage

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?

BridgeBio Oncology Therapeutics, Inc. (BBOT) is highlighted as a promising cancer stock due to its differentiated oncology pipeline, particularly its KRAS-targeted programs like BBO-8520. Oppenheimer initiated coverage with an Outperform rating and a $22 price target, citing enco

Tone
Positive 72/100
Event
Analyst action
Published
30 Jun 2026 13:06
Source
Market source
TradingView Direct company coverage

BBOT Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for BridgeBio Oncology Therapeutics, Inc. (BBOT) stock based on analyst opinions. It details historical price performance, current market capitalization, and financial data such as recent earnings and revenue. The article also incl

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 13:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of BridgeBio Oncology Therapeutics, Inc. – BOATS:BBOT

This article provides a financial overview of BridgeBio Oncology Therapeutics, Inc. (BBOT) on TradingView. It appears to be a stub or an incomplete data page, focusing on the "Price to sales forward" metric. The content indicates the market status as closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of BridgeBio Oncology Therapeutics, Inc. – NASDAQ:BBOT

This article provides access to the "Price to book forward" financial metric for BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) through TradingView. It highlights the company's stock market presence on Nasdaq and confirms that the market was closed with no trades at the tim

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:41
Source
TradingView
TradingView Direct company coverage

BridgeBio Oncology Therapeutics, Inc. Actuals & Estimates (NASDAQ:BBOT)

This article provides a financial overview and analyst estimates for BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT). It covers the company's current stock price, recent performance, analyst price targets, historical highs and lows, market capitalization, and upcoming earning

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

BridgeBio Oncology (BBOT) registers 63.05M shares for selling holders

BridgeBio Oncology Therapeutics, Inc. (BBOT) has registered 63.05 million shares of Common Stock for resale by selling securityholders, as detailed in Prospectus Supplement No. 8 dated June 22, 2026. This supplement also includes governance items from the June 16, 2026 annual mee

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

Michelle Doig resigns from BridgeBio Oncology Therapeutics board effective June 16, 2026

Michelle Doig has resigned from the Board of Directors of BridgeBio Oncology Therapeutics (BBOT) upon completing her Class I term, effective June 16, 2026. Her resignation was not due to any disagreement with the company's operations, policies, or practices. The company has not d

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:39
Source
TradingView
Stock Titan Direct company coverage

BridgeBio Oncology (NASDAQ: BBOT) reports 2026 director elections and auditor ratification

BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) reported the results of its June 16, 2026 Annual Meeting of Stockholders. Shareholders elected Peter Lebowitz and Frank P. McCormick as Class I directors and ratified the appointment of Deloitte & Touche LLP as the independent

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 19:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

BridgeBio Oncology Therapeutics, Inc.(NasdaqGM:BBOT) added to S&P Biotechnology Select Industry Index

BridgeBio Oncology Therapeutics, Inc. (NasdaqGM:BBOT) has been added to the S&P Biotechnology Select Industry Index. This news follows a series of recent updates for the company, including Q1 2026 financial results, inducement grants, and preclinical data presentations for its pi

Tone
Positive 76/100
Event
Earnings
Published
21 Jun 2026 21:31
Source
www.marketscreener.com
Stock Titan Direct company coverage

Director at BridgeBio Oncology (BBOT) receives 7,289 stock options

A director at BridgeBio Oncology Therapeutics (BBOT), Peter F. Lebowitz, was granted 7,289 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Mee

Tone
Neutral 50/100
Event
Market update
Published
20 Jun 2026 07:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at BridgeBio Oncology (BBOT) granted options for 31,675 shares

BridgeBio Oncology Therapeutics director Praveen P. Tipirneni was granted stock options for 31,675 shares of Common Stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036. They will vest fully on the earlier of the first anniversary of the grant

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 17:11
Source
Stock Titan
Stock Titan Direct company coverage

Chen Bihua, director, granted 31,675 options at BridgeBio Oncology (BBOT)

BridgeBio Oncology Therapeutics (BBOT) director and 10% owner Chen Bihua was granted 31,675 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. These options vest upon the earlier of the first anniversary of the grant date or the next Annual Meetin

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 16:40
Source
Stock Titan
Stock Titan Direct company coverage

BridgeBio Oncology (BBOT) director awarded 31,675 options at $7.73 strike

BridgeBio Oncology Therapeutics director Raymond J. Kelleher was granted 31,675 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. The options vest in full on the earlier of the first anniversary of the June 16, 2026 grant date or the next Annual

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 06:11
Source
Stock Titan